Vial Announces Dosing of First Patient in Phase 1 Healthy Volunteer Trial
Vial Logo

Next-Generation Pharma Company

Focused on advancing a pipeline of potentially best-in-class biologics and RNA therapeutics across areas of unmet need

Get in touch

Pipeline

INHBE (Activin E)

Phase 1

Indication

Obesity

Est. Ph I Initiation

H2 2025

Modality

siRNA
Learn More Read Press Release

IL-13 x TSLP

Preclinical

Indication

Atopic Dermatitis, Asthma, Chronic Sinusitis

Est. Ph I Initiation

H2 2025

Modality

Half-life extended bi-specific antibody
Learn More

TMPRSS6​

Preclinical

Indication

Polycythemia Vera

Est. Ph I Initiation

Q1 2026

Modality

siRNA
Learn More

Myostatin (GDF8)

Preclinical

Indication

Obesity

Est. Ph I Initiation

H2 2025

Modality

Half-life extended monoclonal antibody
Learn More

α4β7 x IL-23

Preclinical

Indication

Inflammatory bowel disease (IBD)

Est. Ph I Initiation

H2 2025

Modality

Bi-specific antibody
Learn More
Get in touch

Our model is powered by a computational discovery engine and highly automated clinical trials

Clip art of grey boxes with purple symbols and fake code
Clip art of grey boxes with purple symbols and fake code
molecule-icon

Computationally Enabled Discovery.

Computationally enabled discovery platform delivers programs with best-in-class, differentiated profiles at-scale.

Flowchart
Flow chart moving left to right showing the flow of records

Automated Clinical Trials.

Leveraging technology to automate clinical trials, enhancing precision and efficiency in drug development.

Recent Updates

It’s clear the next breakthrough in obesity treatment will come from entirely new mechanisms that go beyond appetite suppression like VIAL-INHBE. Hear more from Dr. Jens Juul Holst, Professor at the Department of Biomedical Sciences and Senior Group Leader at Novo Nordisk Foundation Center for Basic Metabolic Research.

VIAL-INHBE’s selective fat reduction and muscle preservation is a profile with meaningful clinical potential. Dr. Massimo Volpe, Professor of Cardiology at the University of Rome Sapienza, shares his perspective on why this approach could transform patient care.

Dr. Jason Fung: Treating obesity means more than weight loss – it’s about correcting metabolic disease. VIAL-INHBE can help obese and overweight populations avoid major health issues.

Load More
View Updates

Stay updated on recent news and upcoming events.

Open Positions

Join our team in reimagining drug development.
Explore Roles